Pieris AG, which is developing a platform based of high penetration lipocalins called Anticalins, has appointed Laurent Audoly as chief scientific officer.
Dr Audoly comes from Merck & Co where he had the title of Biologics Research Site Lead. He has experience developing both pharmaceutical and biologic products.
The company’s lead product, PRS-050, is one of several anti-Vascular Endothelial Growth Factor products used to treat solid tumours. However, the company’s preclinical studies indicate that it may have a superior efficacy and safety profile.
Copyright 2010 Evernow Publishing Ltd